Dihydrofolate Reductase antibody (AA 1-186)

Catalog No. ABIN968119

This Mouse Monoclonal antibody specifically detects Dihydrofolate Reductase in WB, IHC, IF and IP. It exhibits reactivity toward Human, Mouse, Rat and Dog and has been mentioned in 5+ publications.

Quick Overview for Dihydrofolate Reductase antibody (AA 1-186) (ABIN968119)

Target: Dihydrofolate Reductase (DHFR)

Reactivity: Human, Mouse, Rat, Dog

Host: Mouse

Clonality: Monoclonal

Conjugate: This Dihydrofolate Reductase antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP)

Clone: 49-DHFR

Product Details anti-Dihydrofolate Reductase Antibody

Binding Specificity: AA 1-186

Cross-Reactivity: Mouse (Murine), Human, Dog (Canine), Rat (Rattus)

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: Cow DHFR aa. 1-186

Isotype: IgG1

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 250 μg/mL

Buffer: Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store undiluted at -20°C.

References for anti-Dihydrofolate Reductase antibody (ABIN968119)

Eymin, Gazzeri, Brambilla, Brambilla: "Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma." in: Oncogene, Vol. 20, Issue 14, pp. 1678-87, (2001) (PubMed).

de Wind, Dekker, Claij, Jansen, van Klink, Radman, Riggins, van der Valk, vant Wout, te Riele: "HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions." in: Nature genetics, Vol. 23, Issue 3, pp. 359-62, (1999) (PubMed).

Tang, Pao, Zhang: "Repair of benzo(a)pyrene diol epoxide- and UV-induced DNA damage in dihydrofolate reductase and adenine phosphoribosyltransferase genes of CHO cells." in: The Journal of biological chemistry, Vol. 269, Issue 17, pp. 12749-54, (1994) (PubMed).

Israel, Kaufman: "Dexamethasone negatively regulates the activity of a chimeric dihydrofolate reductase/glucocorticoid receptor protein." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, Issue 9, pp. 4290-4, (1993) (PubMed).

Masters, Attardi: "The nucleotide sequence of the cDNA coding for the human dihydrofolic acid reductase." in: Gene, Vol. 21, Issue 1-2, pp. 59-63, (1983) (PubMed).

Target Details for Dihydrofolate Reductase

Target: Dihydrofolate Reductase (DHFR)

Alternative Name: DHFR

Background: Dihydrofolate reductase (DHFR) regenerates tetrahydrofolate from dihydrofolate in the presence of NADPH. Tetrahydrofolate is the coenzyme for thymidilate synthetase in the biosynthesis of thymidine and is also critical for the synthesis of amino acids and purines. DHFR is a protein of 186 amino acids that is highly conserved among different organisms. DHFR levels change during the cell cycle, with the highest content during the G1/S transition. Expression of DHFR tightly correlates with the turnover rate of its mRNA. Because dividing cells require a continuous supply of thymidine, DHFR has been a target for anticancer drugs. The folic acid antagonists aminopterin and amethopterin (methotrexate), widely used in cancer treatments, inhibit DHFR. However, over long treatments, treated cells often amplify the DHFR gene, producing drug-resistant cells.

Molecular Weight: 21 kDa

Pathways: Mitotic G1-G1/S Phases